Q-omics provides the consensus-scored OSTC profile across patient tissues and cancer cell-line models. OSTC expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, OSTC is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, OSTC RNA expression shows 19,280 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where OSTC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OSTC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OSTC survival associations across molecular data types. OSTC RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OSTC RNA expression–survival associations across cancer types. High OSTC expression shows unfavorable associations in KIRP, ACC, SCLC, CESC and HNSC, but favorable associations in UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for OSTC RNA expression.
This table summarizes OSTC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for OSTC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OSTC shows higher tumor expression in HNSC, KIRC, BLCA, LUAD, KIRP and LUSC. The HNSC box plot shows higher OSTC RNA expression in tumor versus normal tissue (log2 FC = +1.144, t-test p < 0.001).
This table shows molecular features associated with OSTC in patient tissues and cancer cell lines. In patient samples, OSTC shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, OSTC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
